Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.56 |
| ▸ | LCK | P06239 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29477147 | 0.90 | FGFR1 (0.64) | FGFR1LCKMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL1679608 | 0.89 | LCK (0.49) | FGFR1LCKROCK1IRAK4POLB | |
| SCHEMBL4813477 | 0.80 | POLB (0.60) | FGFR1LCKROCK1IRAK4POLB | |
| SCHEMBL2669851 | 0.80 | LCK (0.43) | FGFR1LCKROCK1IRAK4POLB | |
| SCHEMBL2646370 | 0.80 | HPGD (0.41) | FGFR1LCKROCK1IRAK4POLB | |
| SCHEMBL28571576 | 0.78 | POLB (0.66) | FGFR1LCKMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2669576 | 0.78 | GABRA1 (0.48) | FGFR1LCKROCK1IRAK4POLB | |
| SCHEMBL2658143 | 0.75 | FGFR1 (0.63) | FGFR1MAPTALDH1A1IRAK4POLB | |
| SCHEMBL2311242 | 0.72 | FGFR1 (1.00) | FGFR1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3299749 | 0.72 | FGFR1 (0.66) | FGFR1LCKMAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| US-8329737-B2 | Benzimidazoles as selective kinase inhibitors | YM BIOSCIENCES AUSTRALIA PTY LTD (AU) | 2012-12-11 | — | — | US | disclosed |
| EP-1704145-B1 | SELECTIVE KINASE INHIBITORS | YM BIOSCIENCES AUSTRALIA PTY (AU) | 2012-06-13 | — | — | EP | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | CYTOPIA RESEARCH PTY LTD (AU) | 2011-04-07 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
| US-20080207613-A1 | Selective Kinase Inhibitors | CYTOPIA RESEARCH PTY LTD (AU) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082142-A1 | SELECTIVE KINASE INHIBITORS | LCK, CHUK, CSK | FGFR1 141/4885LCK 1/4885MAPT 2343/4885 |
| US-20080207613-A1 | Selective Kinase Inhibitors | LCK, CHUK, CSK | FGFR1 141/4885LCK 1/4885MAPT 2343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.